Chiome Bioscience Inc. (TYO:4583)

Japan flag Japan · Delayed Price · Currency is JPY
113.00
-3.00 (-2.59%)
At close: Feb 6, 2026
-54.44%
Market Cap7.73B -57.5%
Revenue (ttm)727.99M +25.3%
Net Income-905.53M
EPS-13.54
Shares Out68.44M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume268,000
Average Volume477,910
Open114.00
Previous Close116.00
Day's Range113.00 - 115.00
52-Week Range105.00 - 260.00
Beta0.37
RSI48.50
Earnings DateFeb 10, 2026

About Chiome Bioscience

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology for generating monoclonal antibodies which is used to generate antibodies for drug discovery research; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. It also provides protein expression and purification services; stable cell line development services for recomb... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 53
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4583
Full Company Profile

Financial Performance

In 2024, Chiome Bioscience's revenue was 780.81 million, an increase of 14.41% compared to the previous year's 682.46 million. Losses were -1.02 billion, -16.33% less than in 2023.

Financial Statements